Northern Trust Corp Inhibrx, Inc. Transaction History

Northern Trust Corp

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$32.76 - $39.56 $207,960 - $251,126	-6,348 Reduced 2.02%	307,541 $10.8 Million
Q4 2023 Feb 13, 2024	SELL	$14.5 - $38.0 $22,170 - $58,102	-1,529 Reduced 0.48%	313,889 $11.9 Million
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $213,869 - $357,263	-13,579 Reduced 4.13%	315,418 $5.79 Million
Q2 2023 Aug 11, 2023	BUY	$16.96 - $27.82 $184,372 - $302,431	10,871 Added 3.42%	328,997 $8.54 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $113,264 - $166,612	6,139 Added 1.97%	318,126 $6 Million
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $722,363 - $1.19 Million	35,796 Added 12.96%	311,987 $7.69 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $185,418 - $395,976	16,012 Added 6.15%	276,191 $4.96 Million
Q2 2022 Aug 12, 2022	BUY	$8.52 - $25.26 $51,128 - $151,585	6,001 Added 2.36%	260,179 $2.95 Million
Q1 2022 May 13, 2022	SELL	$19.89 - $43.18 $140,244 - $304,462	-7,051 Reduced 2.7%	254,178 $5.66 Million
Q4 2021 Feb 08, 2022	BUY	$26.75 - $46.02 $155,123 - $266,869	5,799 Added 2.27%	261,229 $11.4 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $241,551 - $362,711	9,593 Added 3.9%	255,430 $8.51 Million
Q2 2021 Aug 13, 2021	BUY	$14.69 - $27.52 $2.2 Million - $4.13 Million	149,977 Added 156.45%	245,837 $6.77 Million
Q1 2021 May 12, 2021	SELL	$16.27 - $41.26 $54,341 - $137,808	-3,340 Reduced 3.37%	95,860 $1.92 Million
Q4 2020 Feb 11, 2021	BUY	$15.96 - $50.0 $1.58 Million - $4.96 Million	99,200 New	99,200 $3.27 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.